Salicylamide O-acetic acid

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Salicylamide O-acetic acid is a salicylate indicated in combination with local anesthetics and corticosteroids for short term treatment of inflammation.

Generic Name
Salicylamide O-acetic acid
DrugBank Accession Number
DB16000
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 195.174
Monoisotopic: 195.053157774
Chemical Formula
C9H9NO4
Synonyms
  • 2-Carbamoylphenoxyacetic acid
  • Salamidacetic acid
  • Salicylamide-2-acetic acid
External IDs
  • 246-940-7
  • NSC-65589

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Rheumesser 3 ml - AmpullenSalicylamide O-acetic acid (150 mg/3mL) + Cyanocobalamin (2.5 mg/3mL) + Dexamethasone (3.5 mg/3mL) + Kebuzone (450 mg/3mL) + Lidocaine (5 mg/3mL)Injection, solutionIntramuscularG.L. Pharma Gmb H1983-08-29Not applicableAustria flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
5LB8V0RHJV
CAS number
25395-22-6
InChI Key
RLISWLLILOTWGG-UHFFFAOYSA-N
InChI
InChI=1S/C9H9NO4/c10-9(13)6-3-1-2-4-7(6)14-5-8(11)12/h1-4H,5H2,(H2,10,13)(H,11,12)
IUPAC Name
2-(2-carbamoylphenoxy)acetic acid
SMILES
NC(=O)C1=C(OCC(O)=O)C=CC=C1

References

General References
  1. BASG: Rheumesser 3 ml - Ampullen (Cyanocobalamin, Dexamethason, Kebuzone, Lidocaine, Salicylamide O-acetic acid) Intramuscular Injection [Link]
ChemSpider
84035
ChEBI
134850
ChEMBL
CHEMBL1700554
ZINC
ZINC000000051262

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.59 mg/mLALOGPS
logP0.25ALOGPS
logP0.14Chemaxon
logS-2.1ALOGPS
pKa (Strongest Acidic)3.27Chemaxon
pKa (Strongest Basic)-0.94Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area89.62 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity47.68 m3·mol-1Chemaxon
Polarizability18.28 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a6r-0900000000-1ec720718ed46d63e6d8
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0zgi-0900000000-f2807064ea04ff0934cb
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0zi3-5900000000-948aac4ab8f1976ddf65
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-3900000000-68971c8b7cdfeb2e493e
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0pb9-0900000000-8ebe0dae6ce433f3f057
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-8b94da387a3e84f06189
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-147.093229
predicted
DarkChem Lite v0.1.0
[M+H]+148.057129
predicted
DarkChem Lite v0.1.0
[M+Na]+148.078429
predicted
DarkChem Lite v0.1.0

Drug created at December 10, 2020 20:45 / Updated at May 05, 2021 20:32